CDTX Cidara Therapeutics

Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020.

Presentation Information:

Date: Thursday, June 18, 2020
Time: 3:40 PM ET
Webcast: A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at

About Cidara Therapeutics

Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit .

INVESTOR CONTACT:

Brian Ritchie

LifeSci Advisors

(212) 915-2578

MEDIA CONTACT:

Karen O’Shea, Ph.D.

LifeSci Communications

(929) 469-3860

 

EN
11/06/2020

Underlying

CDTXCidara Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cidara Therapeutics

 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Reacquires Global Development and Commercial Right...

Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET ...

12h / 33m 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma...

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional approximately $61 million in forecasted obligations through the patent life of rezafungin Cidara to further focus on advancing Cloudbreak development programs, including a planned IND filing for its lead oncology candidate, CBO421, as well a...

12h / 37m 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quart...

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided an update on its corporate activities and product pipeline. “...

April 22, 2024 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced on April 17, 2024, that the Company received a notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising the Company that its failure to timely file its Annual Report o...

April 22, 2024 1 EN
 PRESS RELEASE
Free
CDTX Cidara Therapeu...

Cidara Therapeutics Announces Reverse Stock Split

Cidara Therapeutics Announces Reverse Stock Split SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20. The effective time of the reverse stock split will be 5 p.m. ET on April 23, 2024. The Company’s co...

April 22, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch